TIDMEKF

RNS Number : 2099D

EKF Diagnostics Holdings PLC

20 June 2023

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Enzyme fermentation capacity expansion progress

Factory Acceptance Testing on largest 14,500L fermenter completed and on track for delivery this month

Validation process on other fermenters remains on track for operational activity from summer 2023

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that its Life Sciences division's new 14,500L enzyme fermenter has successfully completed Factory Acceptance Testing. This will be the Company's largest fermenter in its capacity expansion programme, and is scheduled for delivery this month, with installation and validation to be completed in Q3 2023.

In addition, and as planned, the validation process has begun for the new 65L, 300L, 1,500L, and 3,000L fermenters, which are now all on site in the Life Sciences facility in South Bend, Indiana. This range of smaller fermenters, remain on track to be operational and revenue generating over the summer.

Julian Baines, Executive Chair, commented: "Following the successful ISO 13485:2016 and 9001:2015 audits across both of our Life Science sites last month, we're delighted that we continue to make good progress on our capacity expansion plans. We remain on track to have all of our new fermentation capacity in South Bend installed and validated towards the end of Q3 2023, with all but the largest fermenter becoming operational over the summer."

 
EKF Diagnostics Holdings plc                                  www.ekfdiagnostics.com 
Julian Baines, Executive Chair / Marc                       Tel: +44 (0)29 2071 0570 
 Davies, CFO 
 
Singer Capital Markets (Nominated Adviser &                 Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / George Tzimas / Oliver 
 Platts 
 
Walbrook PR Limited                   Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 
                                                                                 303

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is an AIM-listed global diagnostics business focussed on:

-- Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

-- Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCMZGMVVLGGFZM

(END) Dow Jones Newswires

June 20, 2023 02:00 ET (06:00 GMT)

EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more EKF Diagnostics Charts.
EKF Diagnostics (AQSE:EKF.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more EKF Diagnostics Charts.